Investment Thesis
Altimmune is a pre-revenue stage biopharmaceutical company with severe financial distress, burning $67.5M in annual operating cash flow against only $43.8M in cash reserves. The company generated minimal revenue ($41K) with catastrophic operating losses of $94.5M, indicating no viable commercialized products and unsustainable cash burn rate that threatens near-term viability. Without significant funding or breakthrough clinical results, the company faces acute liquidity risk within 12 months.
ALT Strengths
- Strong balance sheet structure with low debt-to-equity ratio of 0.15x limiting leverage risk
- Adequate equity cushion of $224.9M providing some runway for operations
- High liquidity ratios (18.55x current ratio) for near-term obligation coverage
ALT Risks
- Catastrophic cash burn of $67.5M annually with only $43.8M cash on hand creates imminent liquidity crisis
- Virtually no revenue generation ($41K) indicates no commercialized products or market traction
- Operating losses of $94.5M with negative operating margin of -230,461% demonstrate fundamental unprofitability
Key Metrics to Watch
- Monthly cash burn rate and cash runway duration
- Clinical trial progress and FDA approval milestones
- Quarterly revenue growth from potential product launches
ALT Financial Metrics
ALT Profitability Ratios
ALT Balance Sheet & Liquidity
ALT 5-Year Financial Trend
5-Year Trend Summary: Altimmune, Inc.'s revenue has declined by 24% over the 5-year period, indicating business contraction. The most recent EPS of $-1.34 indicates the company is currently unprofitable.
ALT Growth Metrics (YoY)
ALT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.0K | -$19.0M | $-0.21 |
| Q2 2025 | $5.0K | -$19.6M | $-0.27 |
| Q1 2025 | $5.0K | -$19.6M | $-0.26 |
| Q3 2024 | $5.0K | -$16.1M | $-0.32 |
| Q2 2024 | $5.0K | -$16.1M | $-0.32 |
| Q1 2024 | $5.0K | -$20.1M | $-0.34 |
| Q3 2023 | $2.0K | -$16.1M | $-0.39 |
| Q2 2023 | $6.0K | -$16.1M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ALT Capital Allocation
ALT SEC Filings
Access official SEC EDGAR filings for Altimmune, Inc. (CIK: 0001326190)